Randomised controlled study of iron supplementation to support the response to recombinant human erythropoietin for the treatment of chemotherapy-induced anaemia

Barts and the London NHS Trust (UK)0 个研究点目标入组 80 人开始时间: 2007年5月4日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Any patients with a haemoglobin of less than or equal to 10.5 g/dl who is going to receive at least six more weeks of chemotherapy for any non-myeloid malignancy
•2. Any patients with a percent saturation of transferrin more than or equal to 20% and a serum ferritin between 225 and 2250 pmol/L. Confirmatory data will include a reticulocyte haemoglobin content (CHR) more than 31 and zinc protoporphyrin (ZPP) less than 80
•3. Patients must be able to understand and signed written informed consent
•4. An Eastern Cooperative Oncology Group (ECOG) performance status of zero to two

•1. Patients with an anaemia of origin other than cancer or cancer chemotherapy
•2. Prior intravenous (IV) iron therapy
•3. Expectation of actual transfusion requirement during the course of the study. A transfusion given after randomisation wil be a study endpoint for that patient.
•4. Allergy or intolerance to recombinant erythropoietin
•5. Uncontrolled hypertension
•6. Active infection
•7. Primary bone marrow malignancies except for multiple myeloma, chronic lymphocytic leukaemia and indolent non Hogkin's lymphoma, where erythropoiesis-stimulating agents (ESA) therapy has been proven to be beneficial

发起方

Barts and the London NHS Trust (UK)